Adagene Inc. (ADAG), Monday announced updated data from Phase 1b/2 study of Muzastotug in combination with Merck's Keytruda for the treatment of microsatellite stable colorectal cancer (MSS CRC).
This Phase 1b/2, expansion combination study of Muzastotug in combination with Keytruda (200 mg, every 3 weeks) in MSS CRC with no liver and peritoneum metastases previously demonstrated efficacy at the 10 mg/kg every 3 weeks dose, with overall response rate (ORR) of 23 percent. Newly data showed that with the 20 mg/kg loading dose followed by 10 mg/kg every 3 weeks in combination with Keytruda achieved an improved ORR of 33 percent.
Additionally, the company noted that no Grade 4/5 treatment related adverse events were observed and no discontinuations occurred to date.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.